Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Zytiga interactions

Three standard of care compounds widely used against PrCa were added as controls; namely, the androgen receptor antagonist enzalutamide (MDV3100), the C17α-hydroxylase/C17,20-lyase inhibitor abiraterone (Zytiga), and the classic mitotic inhibitor Paclitaxel. [source, 2015]
The two approved medications, enzalutamide (MDV, XTANDI) and abiraterone acetate (Zytiga), work as an AR signaling inhibitor and a CYP17A1 steroidogenesis inhibitor, respectively. [source, 2015]
Recently sipuleucel-T [4], cabazitaxel [5], abiraterone (Zytiga) [6], and MDV3100 [7] have shown more prolonged overall survival benefit and have been approved by the FDA for treatment of the disease. [source, 2015]
Nowadays, oral abiraterone acetate (Zytiga, Janssen Biotech Inc., Horsham, PA, USA) is used in combination with Prednisone or Prednisolone in Europe and the United States for metastatic CRPC previously treated with docetaxel-containing chemotherapy [38]. [source, 2014]
Recent advances of FDA approved therapies including Enzalutamide (MDV3100), Zytiga (Abiraterone Acetate) and Radium-223 have displayed potential in the clinic. [source, 2014]
Recently several new drugs have been approved for the treatment of CRPC: Jevtana (cell division inhibitor), Zytiga (CYP17A inhibitor, androgene blockator) and XTANDI (androgen receptor antagonist). [source, 2014]
Two of them - Zytiga and XTANDI, are targeting androgen-dependant axis, thus providing evidence of significant importance of this pathway as a target for treatment. [source, 2014]
Zytiga (abiraterone), Jevtana (cabazitaxel), Xtandi (enzalutamide), Xofigo (radium Ra 223 dichloride), and Provenge (sipuleucel-T) were recently approved (2010–2013) by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of mCRPC. [source, 2014]
Recently two new hormonal therapy agents have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with mCRPC: Abiraterone acetate (Zytiga) [26] and enzalutamide previously known as MDV3100 (now called Xtandi) [27]. [source, 2014]
To determine the effect of NRs on PCa cell growth, androgen-sensitive (LNCaP) and -insensitive (PC-3, C4-2B) and castration-resistant (22Rv1) human prostate cancer cells were treated with NRs (VN/66-1, VNLG-145, -146, -147, -148, -152, -153), VN/14-1, ATRA, 4-HPR, Casodex, Abiraterone acetate (AA) (Zytiga) and MDV3100 (Enzalutamide) (Figure 1) and assessed for cell viability by MTT assay. [source, 2014]